The relationship between gpl40, the membrane C3d receptor (CR2) of human B lymphocytes, and the Epstein-Barr virus receptor (EBVR) was analyzed by using the polyclonal anti-gpl40, previously prepared by immunizing rabbits with highly purified gpl4O (isolated by some of us) from CR2/EBVR-positive Raji cells. Polyclonal anti-gp72, a C3-binding membrane component, not related to the EBVR but also expressed on the Raji cell surface, was used as a control. Binding of rabbit IgG and EBV on cells was assessed by using immunofluorescence techniques with analysis by flow cytofluorometry. A semiquantitative bioassay was also used to measure the EBV binding. Polyclonal monospecific anti-gpl4O
C3-binding membrane component, not related to the EBVR but also expressed on the Raji cell surface, was used as a control. Binding of rabbit IgG and EBV on cells was assessed by using immunofluorescence techniques with analysis by flow cytofluorometry. A semiquantitative bioassay was also used to measure the EBV binding. Polyclonal monospecific anti-gpl4O
IgG inhibits directly the binding of EBV to Raji cells at the same concentration that inhibits the binding of EC3d on cells, whereas a 35 times higher concentration of anti-gp72 IgG or preimmune serum IgG does not. Anti-gp140 IgG treatment also inhibits the induction of EBV-determined nuclear antigen in normal tonsil B lymphocytes or in EBV-negative Ramos cells, whereas high concentrations of anti-gp72 IgG or preimmune serum IgG have no effect. These data strongly suggest that gpl4O, the CR2 of human B lymphocytes, is also the EBVR.
Different lines of evidence have suggested a structural relationship between the receptor for the Epstein-Barr virus (EBVR) and the receptors for the third component of complement (C3) expressed on the human B-lymphocyte surface (1) . Erythrocyte antibody complement, but not erythrocyte antibody, rosette formation was inhibited by EBV preparations. EBV (8, 9) . CR1 could bind to C3b but also could bind to C4b (10) , iC3b, and, to much smaller extent, to C3c (11 CR2 is a specific membrane marker of B lymphocytes and is also expressed on some B-cell-derived lines, such as Raji (14) . A 140,000 Mr nonphosphorylated glycoprotein, gpl40, has been isolated by some of us from the membranes of Raji cells (15) . It was preliminarily identified as a C3b-binding membrane component by its purification on Sepharosebound C3b (15) and its ability to bind to 125I-labeled C3b (16 (22) to suggest that a 140,000-145,000 Mr membrane component could serve as a CR2. None of these monoclonal antibodies could inhibit the interaction of EC3d with the cell surface. However, recently the B2 epitope has been found on the gpl40 molecule recognized by our serum (unpublished data). Also, recent studies have shown that gp72 does not have EBVR activity (23) .
In the present study, we have explored the relationship between gpl40, the membrane CR2 of human B lymphocytes, and EBVR using the rabbit anti-gpl40 IgG. The rabbit anti-gp72 was used as a negative control. Conclusive evi- (27) were used as the virus source: 104 cells per ml were cultured for 14 days at 370C and the EBVcontaining supernatants were harvested and used at a dilution of 1:1 in the semiquantitative absorption experiments. The EBV membrane fluorescence (EMF) test was performed with a concentrated virus preparation as described (28) .
Antibody Preparation. Anti-gpl40 and anti-gp72 antibodies were prepared by immunizing rabbits with highly purified gpl40 and gp72, as described (18) . Briefly, gpl40 was isolated on Sepharose-bound C3b from solubilized membrane components of Raji (15), whereas gp72 was isolated by affinity chromatography from Raji culture media, following a method described by Lambris et al. (17) and to be described elsewhere (unpublished data). Sera by EBV-sero-positive persons were used as the source of anti-EBV-determined nuclear antigen (EBNA) antibody. To EBVR Assay. EBVR expression was tested by the EMF method (2), based on the direct IF staining of receptor-attached viral envelope components, as described in the previous section, and by the semiquantitative bioassay of Sairenji and Hinuma (29) , as modified previously (30) . For the latter purpose, a B95-8 supernatant was used as the virus source.
In 106 Ramos cells, this virus induced 10-15% EBNA-positive cells (31) after 48 hr. Between 106 and 107 cells were suspended in 1 ml of EBV at 4°C during 60 min. Then, cells were removed by centrifugation. The EBNA-inducing capacity of the unabsorbed virus suspension, 48 hr after infection of Ramos target cells, was compared with the residual activity of the same suspension following absorption with graded numbers of test cells. The absorption index (AI) was calculated according to the formula: AI = (% EBNA induction in control -% EBNA induction in test sample)/% EBNA induction in control.
Virus Infection Tests. High-density human tonsil B lymphocytes (106) (26) or Ramos cells (106) were incubated with 1 ml of B95-8 supernatant diluted 1:3 for 60 min at 37°C. After pelleting, the cells were cultivated for 2 days and the staining of EBNA-positive cells was evaluated on fixed smears.
RESULTS
Binding of Anti-gpl40 IgG and Anti-gp72 IgG to Human Cell Lines. The CR2/EBVR-positive Raji and the receptornegative P3HR-1 lines were compared for their stainability with the anti-gpl4O and anti-gp72 polyclonal antibodies. Whereas P3HR-1 was negative with both anti-gp140 and anti-gp72 (Fig. 1 Upper) , Raji was positive with both, but with a different distribution (Fig. 1 Lower) . This is in good agreement with earlier results (unpublished data), showing that 125I-labeled anti-gpl40 IgG binding was only partially anti-gp72 IgG failed to affect either EBV binding or EC3dg-EC3d binding to the same numbers of cells.
The supernatant assay technique (29) gave identical results (Fig. 3) . Anti-gpl40, but not preimmune serum or antigp72 IgG, blocked the ability of Raji cells to absorb EBV. P3HR-1 cells did not absorb EBV either in the presence or absence of the different sera.
EBV Transformation of Normal B Lymphocytes and EBV Conversion of EBV-Negative BL (Ramos) Cells Is Inhibited by Anti-gpl4O (CR2) IgG. As shown in Table 1 , preincubation of the normal lymphocytes with 64 ,ug of anti-gp140 IgG per 106 cells abolished EBNA induction by B95-8 EBV altogether, whereas 12 gg had no detectable effect. Preimmune serum IgG or anti-gp72 IgG, administered at the high concentration of 300 gg, had no effect on the infectability of the lymphocytes. Very similar results were obtained when the EBVnegative Burkitt lymphoma line Ramos was used as the target cell to assess EBV infectability. In these experiments, 32 and 64 gg of anti-gp140 IgG were both effective, whereas 12 ,ug had no significant effect. The B-cell-specific CR2/EBVR may have other interesting properties related to B-cell activation. EBV is a T-cellindependent polyclonal B-cell activator (35, 36) . Recently, Frade et al. (37) have shown that the proliferation of human B lymphocytes could be enhanced in vitro by anti-gpl40 F(ab')2, in the presence of B-cell growth factor, derived from activated T cells. It did not have any mitogenic effect in the absence of T-cell factor. These data suggest that gpl40 (CR2) is a specific membrane site involved in early B-cell activation in synergy with other membrane and/or intracellular events induced by growth factors such as B-cell growth factor or by multipotent agents such as EBV.t tWhile this manuscript was submitted, Fingeroth et al. (38) reported that CR2 is the receptor for EBV. 
